FORM 4	4
--------	---

1(b).

-	Check this box if no	
	longer subject to Section	
	16. Form 4 or Form 5	
	obligations may	F
	continue. See Instruction	г

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

tions may us. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Fint of Type Responses)												
1. Name and Address of I STROME MARK E	2. Issuer Name and Ticker or Trading Symbol Zivo Bioscience, Inc. [OTCQB:ZIVO]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) 1688 MERIDIAN A	^(First) VENUE, SUITE 7	25	B. Date of Earliest Transaction (Month/Day/Year)Officer (give title below)Other (specify below)							/)		
(Street) MIAMI BEACH, FL 33139			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person _X_Form filed by More than One Reporting Person			
(City)	(State)	(Zip)		Table I - N	lon-D	erivative	Securitie	s Acqı	ired, Disposed of, or Beneficially Owned			
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			Execution Date, if Code (A) or Disposed of (D) Owned Following Reported Ownership or Form: B					Beneficial				
			(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
	Conversion	Date (Month/Day/Year)	Execution Date, if	Transaction Code (Instr. 8)		5. Number of Derivative		6. Date Exercisable and Expiration Date		Underlying	. Title and Amount of		Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial Ownership
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	(I) (Instr. 4)	
Common Stock Purchase Warrant	\$ 0.12	10/08/2020		Р		1,500,000		10/08/2020	10/08/2025	Common Stock	1,500,000	\$ 0 <u>(1)</u>	1,500,000	Ι	See footnotes (2) (3)

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
STROME MARK E 1688 MERIDIAN AVENUE SUITE 727 MIAMI BEACH, FL 33139		Х					
STROME MEZZANINE FUND, LP 1688 MERIDIAN AVENUE SUITE 727 MIAMI BEACH, FL 33139		Х					
STROME INVESTMENT MANAGEMENT LP 1688 MERIDIAN AVENUE SUITE 727 MIAMI BEACH, FL 33139		Х					
STROME GROUP, INC. 1688 MERIDIAN AVENUE SUITE 727 MIAMI BEACH, FL 33139		Х					

Signatures

Mark E. Strome	10/09/2020
***Signature of Reporting Person	Date
Mark E. Strome, as President of General Partner, on behalf of Strome Mezzanine Fund, LP	10/09/2020

-**Signature of Reporting Person	Date
Mark E. Strome, as President of General Partner, on behalf of Strome Investment Management, LP	10/09/2020
Signature of Reporting Person	Date
Mark E. Strome, as President, on behalf of Strome Group, Inc.	10/09/2020
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Strome Mezzanine Fund, L.P. ("Strome Mezzanine") entered into a License Co-Development Participation Agreement dated October 8, 2020 (the "Participation Agreement") with Zivo Bioscience, (1) Inc. ("Zivo"), pursuant to which Strome Mezzanine agreed to fund a portion of the budgeted costs for Zivo's work to enter into certain license agreements. As additional consideration for Strome Mezzanine's funding of the Participation Agreement and to encourage Strome Mezzanine's continued investment in Zivo, Zivo issued this warrant to Strome Mezzanine. No valuation of this portion
- of the consideration was assigned. This filing is made on behalf of Strome Mezzanine, Strome Investment Management, LP, Strome Group, Inc., and Mark Strome (together, the "Reporting Persons"). Strome Investment (2) Management, LP is the general partner of Strome Mezzanine. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark Strome is the President and CEO of Strome
- Group, Inc. Strome Investment Management, LP, Strome Group, Inc., and Mark Strome may be deemed to share voting and investment power for the shares held by Strome Mezzanine.
- (3) Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.